BRIEF: Burning Rock returns to revenue growth as loss narrows
Cancer screening company Burning Rock Biotech Ltd. (BNR.US) on Wednesday reported its revenue rose 0.8% in the third quarter year-on-year to 128.6 million yuan ($17.6 million), as it returned to growth after more than a year of declines. Its net loss narrowed to 35.7 million yuan from a 175 million yuan loss a year earlier.
The company said revenue from its in-hospital business, where it processes results for its cancer tests in labs based within hospitals, rose 17% to 63.8 million yuan year-on-year. But revenue from its central laboratory business, which requires testing samples to be sent to off-site labs, fell 25.2% to 40 million yuan.
Burning Rock and its peers have suffered over the last year from an anti-corruption drive in the medical industry. That campaign has taken a big toll on the company’s central laboratory business, which is especially prone to corruption due to its reliance on physician referrals.
By Doug Young
To subscribe to Bamboo Works free weekly newsletter, click here
Related Articles
BRIEF: Autohome slashes headcount as revenue sags
BRIEF: Drinda New Energy rises in Hong Kong trading debut
BRIEF: CATL passes Hong Kong listing hearing
RELATED ARTICLES
-
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Yalla revenue growth returns to double-digits ahead of new gaming push
YALA.US
-
Baozun returns to the black as Gap expansion accelerates
9991.HK BZUN.US
-
Cango gets crypto jolt back to revenue growth, profitability
CANG.US
-
BRIEF: Ubtech revenue grows, loss narrows in 2024
9880.HK
